Specifically, the use of GLP-1RAs results in a reduction in BP (reduction in systolic BP by 1 mmHg with lixisenatide and by 5.4 mmHg with semaglutide) through a natriuretic and vasodilatory effect, likely mediated by the atrial natriuretic peptide, released as a result of binding to specific receptors expressed in the atria [43]
Roughly 2540% of weight lost on these agents is lean mass
Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz PG, Rizzon P
For most patients, FDA-approved medications provide the most reliable way to support long-term goals Compounded semaglutide may be offered in situations where approved medications are unavailable or when more flexibility is needed for individualized dosing
Our vein specialists diagnose and treat a wide range of vein conditions